Phagenesis

Chief Marketing Officer

• Own and continuously evolve the Phagenyx value proposition — grounded in clinical evidence, health economic impact, and the unmet need in post-stroke dysphagia — ensuring it resonates across clinical, operational, and economic buyer audiences.
• Develop and maintain a coherent messaging architecture for all key customer segments: neurologists, speech-language pathologists, stroke coordinators, neurocritical care intensivists, hospital administrators, and payers.
• Ensure consistency and clarity of internal and external communications across all commercial touchpoints.
• Translate complex clinical data (RCT outcomes, guideline recommendations, healthcare economic outcomes) into compelling, accessible commercial narratives.
• Lead brand positioning strategy and ensure all materials reflect the Phagenesis brand identity.
• Design and execute multi-channel demand generation programmes targeting acute care hospitals, comprehensive stroke centres, and neurology/critical care services to build a qualified pipeline of prospective Phagenyx sites.
• Develop and manage digital and field-integrated campaigns leveraging clinical evidence, guideline adoption, and health economic data to drive awareness and inbound interest.
• Build segmentation models and target account frameworks that enable the field to prioritise and penetrate high-value accounts efficiently.
• Establish metrics and dashboards to track lead volume, source quality, and conversion rates; optimise programmes based on performance data.
• Partner with sales leadership to align marketing-generated leads with territory execution priorities.
• Develop commercial programmes and content to accelerate movement through the sales funnel — from initial clinical champion identification through stakeholder alignment, hospital approval, and first patient treatment.
• Build and maintain a suite of objection-handling tools, economic value calculators, ROI models, and payer/reimbursement resources that remove friction at each stage of the deal cycle.
• Partner with Therapy Development Specialists to identify pipeline bottlenecks and develop targeted interventions — whether clinical education, administrative alignment tools, or C-suite-facing business case materials.
• Own the development of account-level business case frameworks addressing the dysphagia cost burden, NTAP reimbursement, and hospital-specific ROI.
• Support proposal development, contract pathways, and formulary/approval processes in collaboration with the field team.
• Develop and maintain a best-in-class suite of implementation and onboarding resources supporting rapid, high-quality site activation — spanning programme initiation, clinical training materials, patient selection tools, and ongoing programme optimisation content.
• Own the commercial content supporting each phase of Phagenesis’s site integration model, ensuring clinical teams, administrators, and champions are equipped to build durable Phagenyx programmes.
• Partner with clinical/medical affairs to develop evidence-based patient selection frameworks, protocols, and outcome tracking materials.
• Build resources supporting multi-service integration (neurology, stroke, critical care, rehabilitation) and facilitate the expansion of Phagenyx use within existing accounts.
• Develop quarterly business review frameworks and outcome reporting tools that help sites demonstrate programme impact and support internal champions.
• Build and maintain a best-in-class library of sales enablement tools including pitch decks, clinical evidence summaries, competitive differentiation resources, and customer-facing leave-behinds.
• Lead development of congress strategy, peer-to-peer programmes, webinar content, and other commercial education events.
• Provide ongoing support to the Therapy Development Specialist team through field ride-alongs, content refreshes, and real-time competitive intelligence.
• Develop KOL relationships and advisory board programming in collaboration with Medical Affairs.
• Own the marketing calendar and ensure alignment between commercial programmes and key commercial moments (guideline launches, congress cycles, product milestones).
• Serve as a strategic thought partner to the VP of Global Marketing and broader commercial leadership, providing market insight, competitive intelligence, and recommendations that inform growth strategy.
• Collaborate with Medical/Clinical Affairs to ensure commercial programmes are evidence-driven, compliant, and integrated with medical education initiatives.
• Monitor the competitive landscape and maintain an up-to-date competitive intelligence framework; develop response strategies as needed.
• Manage marketing budget with rigour and accountability; track spend against outcomes and optimise resource allocation.
• Ensure all marketing materials comply with FDA regulations, legal requirements, and company quality systems.

Director of Marketing

Director

• Build the strategy, infrastructure, and institutional relationships from the ground up across four markets: the United States, DACH, United Kingdom, and Ireland.
• Lead the development of the US reimbursement roadmap.
• Partner with CMRA to synthesise clinical evidence, economic data, and crosswalk analysis in support of CMS submissions and advocacy.
• Drive account-level adherence to correct NTAP billing practices.
• Monitor IPPS rulemaking cycles and MedPAC activity; develop proactive positioning and response strategies.
• Develop and execute market access strategies for the EU, UK (NHS England), and Ireland (HSE).
• Identify reimbursement barriers and accelerants at country level; build and maintain a clear market access roadmap for each region.
• Build the company’s global health economic value proposition from the ground up.

Director of Marketing

Director, Global Market Access – Health Economics